Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.56 |
| ▸ | LCK | P06239 | 6/20 | 0.56 |
| ▸ | TEK | Q02763 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | HCK | P08631 | 10/20 | 0.49 |
| ▸ | FLT3 | P36888 | 7/20 | 0.49 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467009 | 0.95 | LCK (0.54) | SRCLCKTEKKDRHCK | |
| SCHEMBL6463596 | 0.91 | LCK (0.59) | SRCLCKTEKKDRHCK | |
| SCHEMBL6467898 | 0.90 | LCK (0.57) | SRCLCKTEKKDRHCK | |
| SCHEMBL6461186 | 0.88 | LCK (0.54) | SRCLCKTEKKDRHCK | |
| SCHEMBL6460755 | 0.88 | LCK (0.55) | SRCLCKTEKKDRHCK | |
| SCHEMBL6465307 | 0.88 | LCK (0.55) | SRCLCKTEKKDRHCK | |
| SCHEMBL6464951 | 0.87 | LCK (0.55) | SRCLCKTEKKDRHCK | |
| SCHEMBL6460590 | 0.87 | LCK (0.54) | SRCLCKTEKKDRHCK | |
| SCHEMBL6465482 | 0.87 | LCK (0.56) | SRCLCKTEKKDRHCK | |
| SCHEMBL6468169 | 0.87 | LCK (0.54) | SRCLCKTEKKDRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | SRC 46/4885LCK 1/4885TEK 1465/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | SRC 206/4885LCK 6/4885TEK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.